Clinical trials: Campylobacter Infections
Campylobacter Infection
Safety and Immunogenicity of CJCV2 With and Without ALFQ
This is a randomized, double-blind, dose-escalating, outpatient trial in a total of approximately 60 subjects, assigned to 3 cohorts (20 subjects per cohort).
- Trial name
- NCT05500417
- Testing
- ALFQ, CJCV2
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Campylobacter Infections
LMN-101 in a Campylobacter Human Challenge Model
Randomized, double-blind, placebo-controlled, single dose regimen study of LMN-101 followed by Campylobacter jejuni challenge. Subjects will initially, after documentation of informed consent, begin taking their assigned LMN-101…
- Trial name
- NCT04182490
- Testing
- LMN-101
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Campylobacter Jejuni Infection
Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single dose or at one of three dose levels three…
- Trial name
- NCT04098263
- Testing
- LMN-101
- Where
- Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Campylobacter Infections, Irritable Bowel Syndrome
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long…
- Trial name
- NCT03266068
- Testing
- DNA Analysis of Blood Sample, Flexible sigmoidoscopy with colonic biopsies, Small bowel and colonic gastrointestinal permeability
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Dysentery, Diarrhea
Efficacy of Rifaximin in Preventing Campylobacteriosis
This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.
- Conditions
- Dysentery, Diarrhea, Enteric Campylobacteriosis
- Trial name
- NCT02280044
- Testing
- Rifaximin intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Campylobacter Infection
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant.
- Trial name
- CJCV1-01 (NCT02067676)
- Testing
- Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Soil-transmitted Helminthiasis, Schistosomiasis
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system for delivering primary health care in…
- Conditions
- Soil-transmitted Helminthiasis, Schistosomiasis, Strongyloidiasis, Shigellosis
- Trial name
- NIDIAGDigest (NCT02105714)
- Testing
- Stool culturing for pathogenic bacteria, Kato-Katz technique, Baermann technique
- Where
- 7 sites in Côte d’Ivoire, Indonesia and 2 more
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Campylobacter Infections
Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection
The goal of this research is to continue to develop a model of infection with Campylobacter jejuni, a bacterium that causes food and water-borne disease (mainly diarrhea).
- Trial name
- NCT01048112
- Testing
- Campylobacter jejuni strain CG8421
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Campylobacter Infection
ACE393-103 Vaccination Challenge Study
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
- Trial name
- ACE393-103VC (NCT00859716)
- Testing
- ACE393
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Campylobacter Infections
Campylobacter Jejuni Challenge Model Development: Dose Ranging Study
The primary objective of this study is to establish a human Campylobacter jejuni infection model with the following characteristics: 1. Safe application 1.
- Trial name
- NCT00434798
- Testing
- Campylobacter jejuni strains CG8421 and BH-01-0142
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Vermont